HK1049279A1 - Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases comprising all-d peptides - Google Patents

Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases comprising all-d peptides

Info

Publication number
HK1049279A1
HK1049279A1 HK03100407.4A HK03100407A HK1049279A1 HK 1049279 A1 HK1049279 A1 HK 1049279A1 HK 03100407 A HK03100407 A HK 03100407A HK 1049279 A1 HK1049279 A1 HK 1049279A1
Authority
HK
Hong Kong
Prior art keywords
alzheimer
vaccine
peptides
prevention
treatment
Prior art date
Application number
HK03100407.4A
Other languages
Chinese (zh)
Inventor
Chalifour Robert
Hebert Lise
Kong Xianqi
Gervais Francine
Original Assignee
Neurochem (International) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurochem (International) Ltd filed Critical Neurochem (International) Ltd
Publication of HK1049279A1 publication Critical patent/HK1049279A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK03100407.4A 1999-11-29 2003-01-16 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases comprising all-d peptides HK1049279A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16859499P 1999-11-29 1999-11-29
US72484200A 2000-11-28 2000-11-28
PCT/CA2000/001413 WO2001039796A2 (en) 1999-11-29 2000-11-29 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases

Publications (1)

Publication Number Publication Date
HK1049279A1 true HK1049279A1 (en) 2003-05-09

Family

ID=26864284

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100407.4A HK1049279A1 (en) 1999-11-29 2003-01-16 Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases comprising all-d peptides

Country Status (13)

Country Link
EP (1) EP1235587A2 (en)
JP (1) JP2004500354A (en)
KR (2) KR20020073341A (en)
CN (1) CN1433321A (en)
AU (1) AU784312B2 (en)
BR (1) BR0016022A (en)
CA (1) CA2388559A1 (en)
HK (1) HK1049279A1 (en)
IL (1) IL149924A0 (en)
MX (1) MXPA02005576A (en)
NO (1) NO20022531L (en)
NZ (1) NZ540564A (en)
WO (1) WO2001039796A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
KR20080017471A (en) * 2000-02-21 2008-02-26 파멕사 에이/에스 Novel method for down-regulation of amyloid
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
AU2007200047B2 (en) * 2000-07-07 2009-11-26 Bioarctic Neuroscience Ab Prevention and treatment of Alzheimer's disease
US20020115717A1 (en) * 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
US7311893B2 (en) 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1575991A4 (en) * 2002-07-03 2008-03-19 Bio Science International Inc Peptides comprising aromatic d-amino acids and methods of use
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
PE20050627A1 (en) 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
UA96115C2 (en) * 2003-06-23 2011-10-10 Беллас Хелс (Інтернешнл) Лімітед Methods and compositions for treating amyloid-related diseases
TWI357414B (en) * 2003-12-17 2012-02-01 Wyeth Llc Aβ immunogenic peptide carrier conjugates and meth
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
AU2005326962A1 (en) 2004-12-22 2006-08-17 Bellus Health (International) Limited Methods and compositions for treating amyloid-related diseases
KR100851035B1 (en) 2005-08-23 2008-08-11 대한민국 - - Pharmaceutical composition and composition for screening therapeutics to preventing and treating of -amyloid accumulation in brain comprising GCP-Glutamate carboxypeptidase- as an active ingredient method for screening using said composition
WO2007059000A2 (en) 2005-11-10 2007-05-24 Roskamp Research, Llc Modulation of angiogenesis by a-beta peptide fragments
KR101667623B1 (en) 2005-11-30 2016-10-19 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
RU2442793C2 (en) 2005-11-30 2012-02-20 Эбботт Лэборетриз ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES
NZ568384A (en) * 2005-12-12 2011-09-30 Ac Immune Sa Therapeutic vaccine comprising Abeta peptide
JP5145241B2 (en) 2005-12-12 2013-02-13 エフ．ホフマン−ラ ロシュ アーゲー Antibodies against amyloid beta with glycosylation in the variable region
JP5033868B2 (en) 2006-03-23 2012-09-26 バイオアークティック ニューロサイエンス アーベー Improved protofibril selective antibody and use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PT2468770T (en) * 2006-07-14 2018-03-09 Genentech Inc Humanized antibody against amyloid beta.
SG173385A1 (en) 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
SI2074145T1 (en) * 2006-10-02 2017-12-29 Ac Immune S.A. Humanized antibody against amyloid beta
SI2089417T1 (en) 2006-10-12 2015-04-30 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
WO2008133208A1 (en) * 2007-04-20 2008-11-06 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for enhancing immune response with peptide
JP2010528583A (en) * 2007-06-11 2010-08-26 エーシー イミューン ソシエテ アノニム Humanized antibody against amyloid β
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PL2182983T3 (en) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
RU2604181C2 (en) 2007-10-05 2016-12-10 Дженентек, Инк. Using anti-amyloid beta antibody in ophthalmic diseases
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
WO2009143489A2 (en) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2273273A1 (en) * 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease
MX360403B (en) 2010-04-15 2018-10-31 Abbvie Inc Amyloid-beta binding proteins.
RU2607368C2 (en) 2010-07-30 2017-01-10 Ац Иммуне С.А. Safe and functional humanized antibodies
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
HUE053809T2 (en) 2014-07-10 2021-07-28 Bioarctic Ab Improved a-beta protofibril binding antibodies
BR112017024610A2 (en) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag specific affinity antitransferrin receptor antibodies
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
CN114031689A (en) 2015-10-02 2022-02-11 豪夫迈·罗氏有限公司 Bispecific anti-human CD 20/human transferrin receptor antibodies and methods of use
KR20180085736A (en) 2015-11-09 2018-07-27 더 유니버시티 오브 브리티쉬 콜롬비아 Amyloid beta mid-region epitopes and structurally selective antibodies thereto
AU2016353553B2 (en) 2015-11-09 2022-01-20 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008868A1 (en) * 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
NO314086B1 (en) * 1998-05-08 2003-01-27 Gemvax As Peptides and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids and virus vectors encompassing such DNA sequences and their use for the preparation of pharmaceutical preparations for
AU4529800A (en) * 1999-05-05 2000-11-21 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof

Also Published As

Publication number Publication date
BR0016022A (en) 2002-08-06
NZ540564A (en) 2007-04-27
JP2004500354A (en) 2004-01-08
CN1433321A (en) 2003-07-30
NO20022531D0 (en) 2002-05-28
EP1235587A2 (en) 2002-09-04
NO20022531L (en) 2002-07-12
IL149924A0 (en) 2002-11-10
WO2001039796A2 (en) 2001-06-07
KR20080059676A (en) 2008-06-30
CA2388559A1 (en) 2001-06-07
WO2001039796A3 (en) 2001-12-06
AU1847301A (en) 2001-06-12
AU784312B2 (en) 2006-03-09
KR20020073341A (en) 2002-09-23
MXPA02005576A (en) 2002-12-13

Similar Documents

Publication Publication Date Title
HK1049279A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases comprising all-d peptides
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
SI1303272T1 (en) Benzothiazole derivatives for the treatment of alzheimer's disease and parkinson's disease
HUP0103654A2 (en) Use of smilagenin and anzurogenin-d for production of pharmaceutical compositions for the treatment of alzheimer's disease
AU2003206413A8 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
HUP9901109A3 (en) Peptide immunogens for vaccination against and treatment of allergy
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
EP1575529A4 (en) Peptides and methods of screening immunogenic peptide vaccines against alzheimer's disease
NO20001869D0 (en) Procedures for the treatment of Alzheimer's disease
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
HUP0004331A3 (en) Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it
AU2003303141A8 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
GB0011410D0 (en) Therapeutic combination for treating Alzheimer's disease
AU2003248660A8 (en) Treatment of vascular dysfunction and alzheimer's disease
AU2729400A (en) Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
GB0011430D0 (en) Acombination of therapeutic agents for treating Alzheimer's Disease
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
EP1181550A4 (en) Methods for the identification of compounds for the treatment of alzheimer's disease
PL377110A1 (en) Prevention and treatment of alzheimer's disease
AU2002357232A1 (en) Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease

Legal Events

Date Code Title Description
AS Change of ownership

Owner name: NEUROCHEM (INTERNATIONAL) LIMITED

Free format text: FORMER OWNER(S): NEUROCHEM, INC

CHPA Change of a particular in the register (except of change of ownership)
CHPA Change of a particular in the register (except of change of ownership)